文献速递遗传性与小管间质肾病慢性肾脏病

常染色体显性多囊肾病早期MCP-1释放增强

Enhanced MCP-1 Release in Early Autosomal Dominant Polycystic Kidney Disease.
PubMed 文献 · Kidney Int Rep · 2021-04-06

本研究为横断面研究,纳入53例基因分型ADPKD患儿与53例年龄、性别、BMI匹配的健康对照,比较血浆copeptin、尿EGF及尿MCP-1水平。结果显示仅尿MCP-1在ADPKD患儿中显著升高,且PKD1突变的人近端小管细胞和PKD1敲除的小鼠集合管细胞MCP-1分泌增加,人胎儿ADPKD肾脏可见明显MCP-1免疫反应性和M2巨噬细胞浸润。提示肾小管MCP-1分泌增加是ADPKD早期事件,可能作为早期疾病严重程度标志物和潜在治疗靶点。

要点

  • ADPKD患儿尿MCP-1显著高于健康对照,血浆copeptin和尿EGF无差异。
  • PKD1突变的人近端小管细胞和PKD1敲除的小鼠集合管细胞MCP-1分泌增加。
  • 人胎儿ADPKD肾脏显示明显MCP-1免疫反应性和M2巨噬细胞浸润。

核心结论

  • 肾小管MCP-1分泌增加是ADPKD的早期事件。
  • MCP-1是早期疾病严重程度标志物和潜在治疗靶点。

研究设计与样本

  • 横断面研究,纳入53例基因分型ADPKD患儿和53例年龄、性别、BMI匹配的健康对照。
  • 检测血浆copeptin、尿EGF和尿MCP-1,并在小鼠集合管细胞、人近端小管细胞及胎儿肾脏组织中研究MCP-1。

主要发现

  • ADPKD患儿与对照的平均(SD)年龄为10.4(5.9)岁 vs 10.5(6.1)岁(P=0.543),eGFR为122.7(39.8) vs 114.5(23.1) ml/min per 1.73 m2(P=0.177)。
  • 血浆copeptin和EGF分泌在两组间相当。
  • 尿MCP-1(pg/mg肌酐)中位数(四分位距)在ADPKD患儿为185.4(213.8),显著高于对照的154.7(98.0)(P=0.010)。
  • 携带杂合PKD1突变的人近端小管细胞和PKD1敲除的小鼠集合管细胞MCP-1分泌增加。
  • 人胎儿ADPKD肾脏显示明显的MCP-1免疫反应性和M2巨噬细胞浸润。

临床怎么用

  • 尿MCP-1或可作为ADPKD早期疾病严重程度的生物标志物。
  • MCP-1通路是ADPKD潜在的早期治疗靶点。

局限性

  • 研究为横断面设计,无法确定因果关系。
  • 样本量有限,仅纳入儿童ADPKD患者。
  • MCP-1作为标志物的临床价值需纵向研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Autosomal dominant polycystic kidney disease (ADPKD) causes kidney failure typically in adulthood, but the disease starts in utero. Copeptin, epidermal growth factor (EGF), and monocyte chemoattractant protein-1 (MCP-1) are associated with severity and hold prognostic value in adults but remain unstudied in the early disease stage. Kidneys from adults with ADPKD exhibit macrophage infiltration, and a prominent role of MCP-1 secretion by tubular epithelial cells is suggested from rodent models. METHODS: In a cross-sectional study, plasma copeptin, urinary EGF, and urinary MCP-1 were evaluated in a pediatric ADPKD cohort and compared with age-, sex-, and body mass index (BMI)-matched healthy controls. MCP-1 was studied in mouse collecting duct cells, human proximal tubular cells, and fetal kidney tissue. RESULTS: Fifty-three genotyped ADPKD patients and 53 controls were included. The mean (SD) age was 10.4 (5.9) versus 10.5 (6.1) years (P = 0.543), and the estimated glomerular filtration rate (eGFR) was 122.7 (39.8) versus 114.5 (23.1) ml/min per 1.73 m2 (P = 0.177) in patients versus controls, respectively. Plasma copeptin and EGF secretion were comparable between groups. The median (interquartile range) urinary MCP-1 (pg/mg creatinine) was significantly higher in ADPKD patients (185.4 [213.8]) compared with controls (154.7 [98.0], P = 0.010). Human proximal tubular cells with a heterozygous PKD1 mutation and mouse collecting duct cells with a PKD1 knockout exhibited increased MCP-1 secretion. Human fetal ADPKD kidneys displayed prominent MCP-1 immunoreactivity and M2 macrophage infiltration. CONCLUSION: An increase in tubular MCP-1 secretion is an early event in ADPKD. MCP-1 is an early disease severity marker and a potential treatment target.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Janssens P, Decuypere JP, De Rechter S, et al. Enhanced MCP-1 Release in Early Autosomal Dominant Polycystic Kidney Disease. Kidney Int Rep. 2021. PMID: 34169210. doi:10.1016/j.ekir.2021.03.893

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。